




Instance: composition-en-7b4681f061a21ab4a530ac7b9667ac82
InstanceOf: CompositionUvEpi
Title: "Composition for elucirem Package Leaflet"
Description:  "Composition for elucirem Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp87fb55251eea8b7cc4b73028d30c3711)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - elucirem"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Elucirem is and what it is used for  </li>
<li>What you need to know before you are given Elucirem </li>
<li>How Elucirem will be given to you </li>
<li>Possible side effects </li>
<li>How to store Elucirem </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What elucirem is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What elucirem is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elucirem is a contrast agent which enhances the contrast of the images obtained during magnetic 
resonance imaging (MRI) examinations. Elucirem contains the active substance gadopiclenol. </p>
<p>It improves the visualisation and delineation of abnormal structures or lesions of certain parts of the body 
and helps in the differentiation between healthy and diseased tissue.<br />
It is used in adults and children (2 years of age and older). </p>
<p>It is given as an injection into your vein. This medicine is for diagnostic use only and will only be 
administered by healthcare professionals experienced in the field of clinical MRI practice. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take elucirem"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take elucirem"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elucirem must not be given to you 
- if you are allergic to gadopiclenol or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions<br />
Talk to your doctor, radiologist or pharmacist before you are given Elucirem:</p>
<ul>
<li>if you had a previous reaction to any contrast agent, </li>
<li>if you have asthma, </li>
<li>if you have a history of allergy (such as hay fever, hives), </li>
<li>if your kidneys do not work properly, </li>
<li>ifyou had seizures (fits) or are being treated for epilepsy, </li>
<li>if you have a disease affecting your heart or your blood vessels. </li>
</ul>
<p>In all these cases, your doctor will decide whether the intended examination is possible or not. If you are 
given Elucirem, your doctor or radiologist will take the necessary precautions and the administration of it 
will be carefully monitored. </p>
<p>Your doctor or radiologist may decide to take a blood test to check how well your kidneys are working 
before making the decision to use Elucirem, especially if you are 65 years of age or older. </p>
<p>Other medicines and Elucirem 
Tell your doctor, radiologist or pharmacist if you are taking, have recently taken or might take any other 
medicines. 
In particular, please inform your doctor, radiologist or pharmacist if you are taking or have recently taken 
medicines for heart and blood pressure disorders such as beta-blocking agents, vasoactive substances, 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists. </p>
<p>Pregnancy and breast-feeding  </p>
<p>Pregnancy 
Tell your doctor or radiologist if you think you are, or might become pregnant as Elucirem should not be 
used during pregnancy unless strictly necessary. </p>
<p>Breast-feeding 
Tell your doctor or radiologist if you are breast-feeding or about to start breast-feeding.<br />
Your doctor will discuss whether you should continue or interrupt breast-feeding for a period of 24 hours 
after you receive Elucirem. </p>
<p>Driving and using machines 
Elucirem has no or negligible effect on the ability to drive and use machines. However, if you feel unwell 
after the examination, you should not drive or use machines. </p>
<p>Elucirem contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per 15 mL vial, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take elucirem"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take elucirem"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elucirem will be injected into your vein using a small needle by a specialised healthcare professional. 
It can be administered by hand or by an automatic injector. </p>
<p>Your doctor or radiologist will determine the dose you will receive and supervise the injection. 
The usual dose of 0.1 mL/kg body weight is the same in adults and children of 2 years and older. </p>
<p>In children, your doctor or radiologist will use Elucirem in vials with a single use syringe to be able to 
have a better precision of the injected volume. </p>
<p>After the injection, you will be kept under supervision for at least 30 minutes. This is the time where most 
undesired reactions (such as allergic reactions) may occur. However, in rare cases, reactions may occur 
after hours or days.  </p>
<p>Use in patients with severe kidney problems 
The use of Elucirem is not recommended in patients with severe kidney problems. However, if it is 
required you should only receive one dose of Elucirem during a scan and you should not receive a second 
injection for at least 7 days. </p>
<p>Use in elderly 
It is not necessary to adjust your dose if you are 65 years of age or older, but you may have a blood test to 
check how well your kidneys are working. </p>
<p>If you receive more Elucirem than you should </p>
<p>It is highly unlikely that you will receive an overdose of Elucirem, as it will be given to you by a trained 
healthcare professional. If it does happen, Elucirem can be removed from the body by haemodialysis 
(blood cleaning). </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, radiologist or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>After the administration of Elucirem, you will be kept under observation. Most side effects occur within 
minutes. There is a small risk that you may have an allergic reaction to it. These effects can occur 
immediately and up to seven days after the injection. Such reactions can be severe and result in shock 
(case of allergic reaction that could put your life in danger). </p>
<p>Tell your doctor, radiologist or health professional immediately if you get any of the following side 
effects as it may be the first signs of a shock:</p>
<ul>
<li>swelling of the face, lips, tongue or throat </li>
<li>lightheadedness (low blood pressure) </li>
<li>breathing difficulties </li>
<li>skin rash </li>
<li>coughing, sneezing or runny nose </li>
</ul>
<p>Possible side effects which have been observed during clinical trials with Elucirem are listed below by 
how likely they are: </p>
<p>Frequency<br />
Possible side effects<br />
Common (may affect up to 1 in 10 people)<br />
Injection site reaction<em> 
Headache 
Uncommon<br />
(may affect up to 1 in 100 people)<br />
Allergic reaction</em><em> 
Diarrhoea 
Nausea (feeling sick) 
Fatigue (tiredness) 
Abdominal pain 
Unusual taste in the mouth 
Feeling of warmth 
Vomiting (being sick) 
</em>Injection site reaction includes: pain, swelling, cold feeling, warm feeling, bruising or redness.<br />
**Allergic reaction may include: inflammation of the skin, reddening of the skin, breathing difficulties, 
voice impairment, throat tightness, throat irritation, abnormal sensation in the mouth, transient reddening 
of the face (early reactions) and puffy eyes, swelling, rash and itching (late reactions). </p>
<p>There have been reports of nephrogenic systemic fibrosis (NSF) (which causes hardening of the skin and 
may affect also soft tissue and internal organs) with other contrast agent containing gadolinium however 
no NSF case has been reported with Elucirem during the clinical trials. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store elucirem"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store elucirem"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the vial or pre-filled syringe label and the 
carton box after  EXP . The expiry date refers to the last day of that month. </p>
<p>This medicine is a clear, colorless to pale yellow solution. 
Do not use this medicine if the solution is not clear or if it contains visible particles. </p>
<p>For vials: This medicine does not require any special storage conditions. 
Chemical and physical in-use stability has been demonstrated for 24 hours at up to 25  C. From a 
microbiological point of view, the product should be used immediately after opening. </p>
<p>For pre-filled syringes: Do not freeze. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw 
away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Elucirem contains<br />
- The active substance is gadopiclenol. Each mL of solution contains 485.1 mg gadopiclenol 
(equivalent to 0.5 mmol of gadopiclenol and to 78.6 mg of gadolinium). 
- The other ingredients are tetraxetan, trometamol, hydrochloric acid (for pH adjustment), sodium 
hydroxide (for pH adjustment) and water for injections. See section 2  Elucirem contains sodium  </p>
<p>What Elucirem looks like and contents of the pack </p>
<p>It is a clear, colourless to pale yellow solution for injection. </p>
<p>It is available in packs including:</p>
<ul>
<li>1 vial containing 3, 7.5, 10, 15, 30, 50 or 100 mL of solution for injection. </li>
<li>25 vials containing 7.5, 10 or 15 mL of solution for injection. </li>
<li>1 or 10 (10 x 1) pre-filled syringes containing 7.5, 10 or 15 mL of solution for injection. </li>
<li>1 pre-filled syringe containing 7.5, 10 or 15 mL of solution for injection with administration set for 
manual injection (one extension line and one catheter). </li>
<li>1 pre-filled syringe containing 7.5, 10 or 15 mL of solution for injection with administration set for 
Optistar Elite injector (one extension line, one catheter and one empty 60 mL-plastic syringe). </li>
<li>1 pre-filled syringe containing 7.5, 10 or 15 mL of solution for injection with administration set for 
Medrad Spectris Solaris EP injector (one extension line, one catheter and one empty 115 mL-
plastic syringe). </li>
</ul>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Guerbet 
15 rue des Vanesses 
93420 Villepinte 
France </p>
<p>Manufacturer 
Guerbet  </p>
<p>16 - 24 rue Jean Chaptal 
93600 Aulnay-sous-Bois 
France </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-7b4681f061a21ab4a530ac7b9667ac82
InstanceOf: CompositionUvEpi
Title: "Composition for elucirem Package Leaflet"
Description:  "Composition for elucirem Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp87fb55251eea8b7cc4b73028d30c3711)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - elucirem"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at få Elucirem </li>
<li>Sådan vil du få Elucirem </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What elucirem is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What elucirem is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elucirem er et kontrastmiddel, som forstærker kontrasten af billederne, der tages under MRI-
undersøgelser. Elucirem indeholder det aktive stof gadopiclenol. </p>
<p>Det forbedrer visualiseringen og afbildningen af unormale strukturer eller læsioner i visse dele af kroppen 
og hjælper med at skelne mellem sundt og sygt væv.<br />
Det bruges til voksne og børn (2 år og derover). </p>
<p>Det gives som en injektion i din vene. Denne medicin er kun til diagnostisk brug og vil kun blive 
administreret af sundhedspersonale med erfaring inden for klinisk MRI-praksis. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take elucirem"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take elucirem"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Elucirem 
- hvis du er allergisk over for gadopiclenol eller et af de øvrige indholdsstoffer i Elucirem (angivet i 
punkt 6). </p>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen, radiologen eller apotekspersonalet, før du får Elucirem:</p>
<ul>
<li>hvis du tidligere har reageret på et kontrastmiddel, </li>
<li>hvis du har astma, </li>
<li>hvis du tidligere har haft allergi (såsom høfeber, nældefeber), </li>
<li>hvis dine nyrer ikke fungerer optimalt, </li>
<li>hvis du har haft krampeanfald eller er i behandling for epilepsi, </li>
<li>hvis du har en sygdom, der påvirker dit hjerte eller dine blodkar. </li>
</ul>
<p>I alle disse tilfælde vil din læge afgøre, om den påtænkte undersøgelse er mulig eller ej. Hvis du får 
Elucirem, vil din læge eller radiolog tage de nødvendige forholdsregler og administrationen af det vil 
blive nøje overvåget. </p>
<p>Din læge eller radiolog kan beslutte at tage en blodprøve for at kontrollere, hvor godt dine nyrer fungerer, 
før beslutningen om at anvende Elucirem træffes, især hvis du er 65 år eller ældre. </p>
<p>Brug af andre lægemidler sammen med Elucirem 
Fortæl det altid til lægen, radiologen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har 
taget andre lægemidler eller planlægger at tage andre lægemidler. 
Især skal lægen, radiologen eller apoteket vide, om du tager eller for nylig har taget lægemidler mod 
hjerte- eller blodtrykslidelser, såsom beta-blokkere, vasoaktive stoffer, angiotensin-konverterende 
enzymhæmmere, angiontensin-II receptorantagonister. </p>
<p>Graviditet og amning  </p>
<p>Graviditet 
Hvis du har mistanke om, at du er gravid eller planlægger at blive gravid, skal du fortælle det til lægen 
eller radiologen, da Elucirem ikke bør anvendes under graviditet, medmindre det er strengt nødvendigt. </p>
<p>Amning 
Fortæl det til din læge eller radiolog, hvis du ammer eller skal begynde at amme.<br />
Din læge vil drøfte, hvorvidt du skal fortsætte amningen eller afbryde den i en periode på 24 timer efter, 
at du har taget Elucirem. </p>
<p>Trafik- og arbejdssikkerhed 
Elucirem har ingen eller ubetydelig indflydelse på evnen til at køre eller anvende maskiner. Hvis du føler 
dig dårlig efter undersøgelsen, skal du dog ikke køre eller anvende maskiner. </p>
<p>Elucirem indeholder natrium 
Denne medicin indeholder mindre end 1 mmol natrium (23 mg) pr. 15 ml hætteglas, det vil sige, at den 
stort set er "natriumfri". </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take elucirem"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take elucirem"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elucirem vil blive injiceret i din vene med en lille nål af specialiseret sundhedspersonale. 
Det kan administreres manuelt eller ved automatisk injektion. </p>
<p>Din læge eller radiolog vil fastsætte den dosis, du vil modtage, og overvåge injektionen. 
Den sædvanlige dosis på 0,1 ml/kg legemsvægt er den samme hos voksne og børn på 2 år og derover. </p>
<p>Hos børn vil din læge eller radiolog vil bruge Elucirem i hætteglas med en engangssprøjte for at opnå en 
bedre præcision af det injicerede volumen. </p>
<p>Efter injektionen vil du blive holdt under opsyn i mindst 30 minutter. Dette er tidspunktet, hvor de fleste 
uønskede reaktioner (såsom allergiske reaktioner) kan forekomme. I sjældne tilfælde kan reaktionerne 
dog opstå efter timer eller dage.  </p>
<p>Anvendelse til patienter med alvorlige nyreproblemer 
Elucirem anbefales ikke til patienter med alvorlige nyreproblemer. Hvis det imidlertid er krævet, vil du 
kun modtage én dosis Elucirem under scanningen, og du må ikke få en anden injektion i mindst 7 dage. </p>
<p>Anvendelse til ældre 
Det er ikke nødvendigt at ændre dosis, hvis du er 65 år eller ældre, men måske skal du have foretaget en 
blodprøve for at kontrollere, om dine nyrer fungerer korrekt. </p>
<p>Hvis du har fået for meget Elucirem 
Det er højst usandsynligt, at du vil få en overdosis af Elucirem, da den vil blive givet til dig af uddannet 
sundhedspersonale. Hvis det alligevel sker, kan Elucirem fjernes fra kroppen ved hæmodialyse 
(blodrensning). </p>
<p>Spørg lægen, radiologen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Efter administration af Elucirem vil du blive holdt under observation. De fleste bivirkninger opstår inden 
for minutter. Der er en lille risiko for, at du kan få en allergisk reaktion af det. Disse bivirkninger kan 
opstå med det samme og op til syv dage efter injektionen. Sådanne reaktioner kan være alvorlige og 
resultere i shock (tilfælde af allergiske reaktioner, der kan bringe dit liv i fare). </p>
<p>Fortæl det straks til din læge, radiolog eller sundhedspersonalet, hvis du får nogle af følgende 
bivirkninger, da det kan være de første tegn på et shock:</p>
<ul>
<li>hævelse af ansigt, læber, tunge eller svælg </li>
<li>svimmelhed (lavt blodtryk) </li>
<li>åndedrætsbesvær </li>
<li>udslæt </li>
<li>hoste, nysen eller løbende næse </li>
</ul>
<p>Mulige bivirkninger, som er blevet observeret under kliniske forsøg med Elucirem, er angivet nedenfor 
efter, hvor sandsynlige de er: </p>
<p>Frekvens<br />
Mulige bivirkninger<br />
Almindelige bivirkninger (kan påvirke 1 ud af 
10 mennesker)<br />
Reaktion på injektionsstedet<em> 
Hovedpine 
Ikke almindelige bivirkninger<br />
(kan påvirke 1 ud af 100 mennesker)<br />
Allergiske reaktioner</em>* 
Diarré 
Kvalme (følelsen af at være syg) 
Træthed 
Mavesmerter 
Udsædvanlig smag i munden 
Følelse af varme 
Opkastning (at være syg) </p>
<p>*Reaktion på injektionsstedet omfatter: smerte, hævelse, kold følelse, varm følelse, blå mærker eller 
rødme.  </p>
<p>**Allergiske reaktioner kan omfatte: betændelse i huden, rødme af huden, åndedrætsbesvær, 
stemmeforstyrrelse, snæverhed i halsen, irritation i halsen, unormal fornemmelse i munden, forbigående 
rødme i ansigtet (tidlige reaktioner) og hævede øjne, hævelse, udslæt og kløe (sen reaktion). </p>
<p>Der er rapporteret om nefrogen systemisk fibrose (NSF) (som forårsager hærdning af huden og kan også 
påvirke blødt væv og indre organer) med andre kontrastmidler indeholdende gadolinium, men der er ikke 
rapporteret om NSF-tilfælde med Elucirem under de kliniske forsøg. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. </p>
<p>Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af 
dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store elucirem"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store elucirem"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar Elucirem utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på hætteglasset eller den fyldte sprøjte og æsken efter 
"EXP" eller "Anv. Inden". Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel er en klar, farveløs til bleggul opløsning. 
Brug ikke dette lægemiddel, hvis opløsningen ikke er klar, eller hvis den indeholder synlige partikler. </p>
<p>Hætteglas: Dette lægemiddel kræver ingen særlige opbevaringsbetingelser. 
Kemisk og fysisk stabilitet under brug er blevet påvist i 24 timer ved op til 25 °C. Ud fra et 
mikrobiologisk synspunkt bør produktet anvendes umiddelbart efter åbning. </p>
<p>Fyldte sprøjter: Må ikke nedfryses. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du ikke 
smide lægemiddelrester i afløbet,toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elucirem indeholder:</p>
<ul>
<li>Aktivt stof: gadopiclenol. Hver ml opløsning indeholder 485,1 mg gadopiclenol (svarende til 
0,5 mmol gadopiclenol og 78,6 mg gadolinium). </li>
<li>Øvrige indholdsstoffer: tetraxetan, trometamol, saltsyre (til pH-justering), natriumhydroxid (til pH-
justering) og vand til injektionsvæsker.  Se afsnit 2 "Elucirem indeholder natriumklorid". </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Det er en klar, farveløs til bleggul injektionsvæske. </p>
<p>Den fås i pakker, herunder:</p>
<ul>
<li>1 hætteglas med 3, 7,5, 10, 15, 30, 50 eller 100 ml injektionsvæske. </li>
<li>25 hætteglas med 7,5, 10 eller 15 ml injektionsvæske. </li>
<li>1 eller 10 (10 x 1) fyldte sprøjter med 7,5, 10 eller 15 ml injektionsvæske. </li>
<li>1 fyldt sprøjte med 7,5, 10 eller 15 ml injektionsvæske med administrationssæt til manuel injektion 
(én forlængerslange og et kateter). </li>
<li>1 fyldt sprøjte med 7,5, 10 eller 15 ml injektionsvæske med administrationssæt til Optistar Elite-
injektor (en forlængerslange, et kateter og en tom 60 ml-plastiksprøjte). </li>
<li>1 fyldt sprøjte med 7,5, 10 eller 15 ml injektionsvæske med administrationssæt til Medrad Spectris 
Solaris EP-injektor (én forlængerslange, et kateter og en tom 115 ml plastiksprøjte). </li>
</ul>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Guerbet 
15 rue des Vanesses 
93420 Villepinte 
Frankrig </p>
<p>Fremstiller 
Guerbet<br />
16 - 24 rue Jean Chaptal 
93600 Aulnay-sous-Bois 
Frankrig </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>
<p>&lt;------------------------------------------------------------------------------------------------------------------------&gt; </p>
<p>Nedenstående oplysninger er kun til sundhedspersoner: </p>
<p>For detaljer om, hvordan produktet skal bruges, henvises til punkt 6.6 Særlige forholdsregler for 
bortskaffelse og anden form for håndtering i produktresuméet for dette produkt. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-7b4681f061a21ab4a530ac7b9667ac82
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for elucirem Package Leaflet for language en"
Description: "ePI document Bundle for elucirem Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-7b4681f061a21ab4a530ac7b9667ac82"
* entry[0].resource = composition-en-7b4681f061a21ab4a530ac7b9667ac82

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7b4681f061a21ab4a530ac7b9667ac82"
* entry[=].resource = mp7b4681f061a21ab4a530ac7b9667ac82
                            
                    
Instance: bundlepackageleaflet-da-7b4681f061a21ab4a530ac7b9667ac82
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for elucirem Package Leaflet for language da"
Description: "ePI document Bundle for elucirem Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-7b4681f061a21ab4a530ac7b9667ac82"
* entry[0].resource = composition-da-7b4681f061a21ab4a530ac7b9667ac82

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7b4681f061a21ab4a530ac7b9667ac82"
* entry[=].resource = mp7b4681f061a21ab4a530ac7b9667ac82
                            
                    



Instance: mp7b4681f061a21ab4a530ac7b9667ac82
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product elucirem"
Description: "elucirem"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1772/001-025"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "This medicinal product is for diagnostic use only."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "elucirem"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 7b4681f061a21ab4a530ac7b9667ac82ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "elucirem"

* status = #current
* mode = #working

* title = "List of all ePIs associated with elucirem"

* subject = Reference(mp87fb55251eea8b7cc4b73028d30c3711)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#elucirem "elucirem"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-7b4681f061a21ab4a530ac7b9667ac82) // elucirem en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-7b4681f061a21ab4a530ac7b9667ac82) // elucirem da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-7b4681f061a21ab4a530ac7b9667ac82
InstanceOf: List

* insert 7b4681f061a21ab4a530ac7b9667ac82ListRuleset
    